<DOC>
	<DOCNO>NCT01514890</DOCNO>
	<brief_summary>The purpose fo study evaluate efficacy define sustain virological response ( SVR ) , patient compensate cirrhosis treat PEG-IFN , RBV telaprevir boceprevir French Early Access Program use protease inhibitor approval drug market authorization .</brief_summary>
	<brief_title>French Cohort Therapeutic Failure Resistances Patients Treated With Protease Inhibitor ( Telaprevir Boceprevir ) , Pegylated Interferon Ribavirin</brief_title>
	<detailed_description>Methodology : Multicentric French national cohort prospective collection data constitution biobank , HCV genotype 1 patient compensated cirrhosis fail eradicate HCV combination PEG-IFN RBV , treat protease inhibitor ( telaprevir boceprevir ) , PEG-IFN RBV , include French Early Access Program use protease inhibitor approval drug market authorization . Primary objective : Evaluate efficacy define sustained virological response ( SVR ) , patient compensate cirrhosis treat PEG-IFN , RBV telaprevir boceprevir French Early Access Program use protease inhibitor approval drug . Estimated enrollment : 900 patient treat French Early Access Program use protease inhibitor market authorization approval . Treatments : - telaprevir : triple combination PEG-IFN alfa-2a , 180 µg/week , ribavirin 1000 1200 mg/d accord body weight telaprevir 750 mg/8h , 12 week follow PEG-IFN RBV 36 week total duration treatment 48 week . - boceprevir : triple combination PEG-IFN alfa-2b , 1,5 µg/kg/week , RBV 800 1400 mg/d accord body weight boceprevir 800 mg/8h . The treatment begin lead phase PEG-IFN RBV 4 week , follow triple combination ( PEG-IFN , RBV boceprevir ) 44 week total duration treatment 48 week . Estimated planning : - study start date : February 2011 - enrollment period : 14 month - subject participation duration : 12 month treatment 12 month follow-up = 24 month - total study duration : 38 month . The last visit last enrolled patient previse February 2014 , end analysis biobank May 2014 ( long term follow resistant mutant ) . Some blood sample preserve scientific future research . Study design : national French multicentric cohort patient HCV-related cirrhosis treat French Early Access Program use boceprevir telaprevir marketing authorization approval drug associate PEG-IFN RBV collection clinical biological data constitution biobank .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>patient need criterion French Early Access Program boceprevir telaprevir marketing authorization approval : patient age 18 year chronic hepatitis C relapsers partialresponders nullresponders treatment PEG'IFN α2a 2b associated RBV chronic infection genotype 1 HCV fibrosis Metavir score 4 ( cirrhosis ) without decompensated liver disease naïve direct antiviral treatment without HIV HBV coinfection signature participation cohort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>